Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 5/20 | 0.54 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | SMO | Q99835 | 7/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2277210 | 0.85 | SMO (0.51) | NR1H2MEN1KMT2AGFERSMO | |
| SCHEMBL4166702 | 0.85 | SMO (0.51) | NR1H2MEN1KMT2AGFERSMO | |
| SCHEMBL1102299 | 0.85 | SMO (0.51) | NR1H2MEN1KMT2AGFERSMO | |
| SCHEMBL1090772 | 0.84 | SMO (0.54) | MEN1KMT2AGFERSMO | |
| SCHEMBL10192612 | 0.83 | NR1H2 (0.41) | NR1H2NR1H3MEN1KMT2AGFER | |
| SCHEMBL15148025 | 0.80 | NR1H2 (0.72) | NR1H2NR1H3MEN1KMT2AGFER | |
| SCHEMBL21886120 | 0.80 | NR1H2 (0.72) | NR1H2NR1H3MEN1KMT2AGFER | |
| SCHEMBL12324594 | 0.80 | NR1H2 (0.72) | NR1H2NR1H3MEN1KMT2AGFER | |
| SCHEMBL25054060 | 0.78 | NR1H2 (0.59) | NR1H2NR1H3 | |
| SCHEMBL30386832 | 0.78 | NR1H2 (0.59) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170866-B1 | PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-2170866-B1 | PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC (US) | 2014-08-13 | — | — | EP | disclosed |
| US-8153633-B2 | Phthalazine compounds, compositions and methods of use | AMGEN INC. (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2170866-A1 | PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Amgen Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090048259-A1 | Phthalazine compounds, compositions and methods of use | AMGEN INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048259-A1 | Phthalazine compounds, compositions and methods of use | AMGEN INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2009002469-A1 | PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048259-A1 | Phthalazine compounds, compositions and methods of use | VHL, HDAC5, SUZ12 | NR1H2 524/4885NR1H3 1104/4885MEN1 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.